Botulin toxin for spasticity in spinal cord damage

Harefuah

Volumn 138, Issue 3, 2000, Pages

  Keren, Ofer ^a   Shinberg, Flabia ^a   Catz, Amiram ^a   Giladi, Neer ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DYSTONIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MUSCLE CONTRACTION; MUSCLE MASS; NERVE BLOCK; SPASTICITY; SPINAL CORD LESION; WELLBEING;

ADULT; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ENDPLATE; MUSCLE SPASTICITY; SPINAL CORD; SPINAL CORD INJURIES;

EID: 0034144427     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Gans BM & Glenn MB, In: Glenn MB & Whyte J, The Practical Management of Spasticity in Children and Adults. Lea & Febiger, Philadelphia, 1990, p 2.
2. Priesbe MM, Sherwood AM & Thornby MM, Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil, 1966; 77: 713-716.
3. Bohannon RW & Smith MB, Interrater reability of a modified Ashworth scale of muscle spasticity. Phys Ther, 1987; 67: 207-207.
4. Berghaus N, Keren O & Bloom A, A protocol for sensory-motor assessment of brain damage patients - I. Review of literature and theoretical basis of the assessment procedure. Eur J Phys Med Rehab, 1995; 5: 147-153.
5. Matthews PBC & Rushworth G, The relative sensitivity of muscle nerve fibers to procaine. J Physiol, 1957; 135: 263-269.
6. Wood KE, The use of phenol as a neurolytic agent: a review. Pain, 1978; 5: 205-229.
7. Tsui JK, Fross RP, Calne S & al, Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci, 1987; 14: 533-535.
8. Grazko MA, Polo B & Jabbari B, Botulinum toxin A for spasticity, muscle spasms and rigidity. Neurology, 1995; 45: 712-717.
9. Giladi N, Meer J, Kidan C & al, Interventional neurology: Botulinum toxin as a potent symptomatic treatment in neurology. Isr J Med Sci, 1994; 30: 1-10.
10. Pierson SH, Katz DI & Tarsy D, Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Rehabil, 1996; 77: 717-721.
11. Frankel HL, Hancock DO, Hyslop & al, The value of postural reduction in initial management of closed injuries to the spine with paraplegia and tetraplegia. Paraplegia, 1969; 7: 179-192.
12. Catz A, Itzkovich M, Agranov E & al, SCIM - Spinal cord independence measure: a new disability scale for patients with spinal cord lesions. Spinal Cord, 1998; 35: 850-856.
13. Zelnik N, Giladi N, Goikhman L & al, The role of Botulinum in the treatment of lower limb spasticity in children with cerebral palsy - a pilot study. Isr J Med Sci, 1997; 33: 129-133.
14. Giladi N, the mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neuro Sci, 1997; 152: 132-135.
15. Filippi GM, Errico P, Santarelli R & al, Botulinum A toxin effects on rat jaw muscle spindeles. Acta Otolaryngol, 1993; 113: 400-404.
16. Henneman E, Somjen G & Carpenter DO, Functional significance of cell size in spinal motor neurons. J Neurophysiol, 1965; 28: 560-580.
17. Shaari CM & Sanders I, Quantifying how location and dose Botulinum toxin injections affect muscle paralysis. Muscle & Nerve, 1998; 16: 964-969.